Q1 2025 Eris Lifesciences Ltd Earnings Call Transcript
Key Points
- Eris Lifesciences Ltd (BOM:540596) achieved a consolidated revenue of INR 720 crores for Q1 FY25, representing a 54% growth year-on-year.
- The company reported a consolidated EBITDA of INR 250 crores for the quarter, reflecting a 47% increase year-on-year.
- The gross margin for the base business improved by nearly 300 basis points to 86% year-on-year.
- The company successfully integrated the Biocon acquisitions ahead of schedule, realizing significant synergies.
- Eris Lifesciences Ltd (BOM:540596) has evolved its business model from a specialty to a specialty plus super specialty model, adding segments like oncology, critical care, and nephrology.
- The cardiac portfolio has been underperforming compared to the IPFs, with challenges in stock availability affecting market performance.
- The gross margin for the consolidated business decreased by more than 800 basis points due to changes in business and product mix.
- The company has a significant net debt of INR 2,700 crores as of June 30, 2024.
- There was a reduction in fixed costs as a percentage of revenue by 660 basis points, but this was offset by a gross margin reduction.
- The effective tax rate for the year is expected to be around 25%, higher than the cash tax rate of 17%.
Ladies and gentlemen, good day, and welcome to the Q1 FY25 earnings conference call of Eris Lifesciences Limited. We have with us on the call today are Mr. Amit Bakshi, Chairman and Managing Director; Mr. V. Krishnakumar, Chief Operating Officer and Executive Director; Mr. Sachin Shah, Chief Financial Officer, and Ms. Kruti Raval, Head, Investor Relations.
(Operator Instructions) Please note this call is being recorded. I now hand the conference over to Mr. V. Krishnakumar, Chief Operating Officer and Executive Director of the company.
Thank you, and over to you. Sir.
Good evening, everybody, and welcome to our Quarter one, conference call. So before we dive into the details, it's probably useful to take a couple of minutes to articulate how we think about our business, how the business is structured. There's been a lot of change in the last few months. And that also gives you a sense of how this presentation is organized. So we have two business
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
